Recent Advances in the Fast-Growing Molecular Diagnostics Industry

Table of Contents

• Executive Summary
  • Strategic Considerations
  • Stakeholder Implications
• Overview
• The Evolution of the MDx Industry
• The Three Phases of the MDx Industry
  • Phase One: Infectious Diseases
  • Phase Two: Blood Screening
  • Phase Three: Pharmacogenomic Testing, Genetic Testing, Predictive Testing, and
  • Companion Diagnostics
    • Pharmacogenomic Testing
    • Predictive Testing
    • Genetic Testing
• Expert Commentary-MDx: Looking Ahead
  • Companion Diagnostics
• MDx Technologies and Platforms
  • MDx Technologies
    • PCR
    • DNA Methylation
    • RNA Interference
  • MDx Platforms
    • Microarrays and Nanoarrays
    • Microfl uidics
    • Multiplex Assays
• Changing Trends
  • Pharmaceutical/MDx Alliances and Acquisitions
  • Support from Regulatory Authorities
  • Alliances Between Diagnostics and Technology-Based Companies
• Regulatory Environment and Advances in MDx
• Key Players in the MDx Field
  • Roche Diagnostics
  • Abbott Diagnostics
  • Bayer Diagnostics/Siemens Medical Solutions Group
• Market Outlook

Tables:

• 1. Select Molecular Diagnostics for Infectious Agents
• 2. The Third Phase of the MDx Industry
• 3. Recent Alliances Between Research Organizations and Pharmaceutical/Biotech Companies
• 4. AmpliChip CYP450 Test
• 5. Select PGx-Based Diagnostic Tests
• 6. Comparison of Molecular Tests
• 7. Select Pharma-Diagnostics Industry Alliances
• 8. Recent Alliances Between Diagnostic and Technology Companies
• 9. Key Mergers and Acquisitions in the MDx Market
• 10. Likely Impact of Increased Uptake of MDx Tests
• 11. Global Market Opportunities for Molecular Diagnostics, 2005-2010
• A. Current and Planned MDx Products at Celera Diagnostics

Figures:

• 1. The Three Phases of the Molecular Diagnostic Industry
• 2. Growth in Alliances Between Academia/Research Organizations and Pharmaceutical/Biotech Companies, 2002-2006
• 3. Select Molecular Diagnostic Technologies and Platforms
• 4. Interrelationship Between Pharmaceutical/Biotech and Molecular Diagnostics Companies
• 5. Future Diversifi cation of the MDx Market